COMMUNIQUÉS West-GlobeNewswire

DIAXONHIT renforce sa présence dans le contrôle de qualité par un partenariat avec RCPAQAP
22/01/2018
DIAXONHIT renforce sa présence dans le contrôle de qualité Signature d'un accord exclusif pour la commercialisation dans toute l'Europe de programmes d'évaluation externe de la qualité des laboratoires de biologie [...]
ProMIS Neurosciences Issues Response to Recent Market Activity
22/01/2018
TORONTO and CAMBRIDGE, Mass., Jan. 22, 2018 (GLOBE NEWSWIRE) -- At the request of IIROC ("Investment Industry Regulatory Organization of Canada"), ProMIS Neurosciences, Inc. (TSX: PMN ) (OTCQB:ARFXF) (the "Company") [...]
Allocation of Share Options
22/01/2018
NASDAQ Copenhagen Report on transactions of executives and related parties in Coloplast shares and related securities. According to the Market Abuse Regulation art. 19 Coloplast is obliged to report on the transactions [...]
Nymox Reports 5-Year Results From Prospective Randomized Controlled Prostate Cancer Study of Fexapotide Triflutate in 146 U.S. Men
22/01/2018
HASBROUCK HEIGHTS, N.J., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX ) reported today top-line 5-year results from Nymox's U.S. Study NX03-0040. Study NX03-0040 was undertaken [...]
Medibio Signs Agreement with Striiv to Accelerate Commercialisation
22/01/2018
Medibio’s proprietary technology to be integrated into Striiv’s mobile app that has 1m+ subscribers Striiv has corporate partnerships with UnitedHealth, Qualcomm Life, and Pfizer SYDNEY, Australia and MINNEAPOLIS, Jan. [...]
The Delta Companies Promotes Paul Estrada to EVP of Delta Physician Placement
22/01/2018
DALLAS, Jan. 22, 2018 (GLOBE NEWSWIRE) -- The Delta Companies (TDC), a leading staffing firm for healthcare professionals nationwide, announced that Paul Estrada has been promoted to Executive Vice President of Delta [...]
Ossur Hf :Transactions in relation to share buyback program
22/01/2018
Announcement from Össur hf. No. 5/2018 Reykjavík, 22 January 2018 On 15 August 2017, Össur hf. initiated a share buy-back program, see Company announcement no. 59/2017. The purpose of the share buyback program is to [...]
BioRestorative Therapies Announces the Appointment of Adam D. Bergstein as Sr. VP, Planning and Business Development
22/01/2018
MELVILLE, N.Y., Jan. 22, 2018 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative" or the “Company") (OTC:BRTX), a life sciences company focused on stem cell-based therapies, today announced the [...]
Peter Carlisle Appointed as Director
22/01/2018
SYDNEY, Australia and MINNEAPOLIS, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Medibio Limited ( MEB or the Company ) (ASX:MEB) (OTCQB:MDBIF) announces that Mr. Peter Carlisle has been appointed to the Board of Directors of [...]
The American Health Council Physician Board Welcomes Domenico Calcaterra, MD, PhD, FACS, FCCP, FACC
22/01/2018
NEW YORK, Jan. 22, 2018 (GLOBE NEWSWIRE) -- The American Health Council proudly welcomes Domenico Calcaterra, MD, Ph.D., FACS, FCCP, FACC, to its Board of Physicians. Dr. Calcaterra is the Chief of Cardiac Surgery at [...]
Imaging3 Announces Addition of Dr. Douglas Beall to the Scientific Advisory Board
22/01/2018
BURBANK, Calif., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Imaging3, Inc. (OTCQB:IGNG), is pleased to announce the addition of Dr. Douglas Beall to the newly formed Scientific Advisory Board (SAB). “As we continue along the [...]
PALIO and GSW to Operate as Singular Advertising Powerhouse Under GSW Brand
22/01/2018
RALEIGH, N.C., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Syneos Health™ (NASDAQ: SYNH ), the only fully integrated biopharmaceutical solutions organization, today announced that two of its advertising agencies, PALIO and GSW, [...]
Abattis Partners with Vancouver-Based Craft Brewer to Develop Hemp-Infused, Cannabinoid-Rich, THC-Free Craft Beer
22/01/2018
VANCOUVER, British Columbia, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Abattis Bioceuticals Corp. (the " Company " or " Abattis ") (CSE:ATT) (OTC:ATTBF) is pleased to announce the formation of a new partnership (the “ [...]
American Heart Association announces Triangle Life is Why sponsorship with Chiesi USA
22/01/2018
RALEIGH, N.C., Jan. 22, 2018 (GLOBE NEWSWIRE) -- The American Heart Association (AHA) proudly announces Chiesi (key-A-zee), a Cary-based specialty pharmaceutical company, as the first Life is Why sponsor in the Triangle [...]
Enrollment Completed in Randomized Clinical Trial of Habeo™ Cell Therapy for Scleroderma and Impaired Hand Function
22/01/2018
SAN DIEGO, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (NASDAQ: CYTX ) announces completion of patient enrollment in SCLERADEC II ( NCT02558543 ), a randomized, double-blind, placebo-controlled, parallel [...]
PHM Announces Expansion & Results of Telemedicine Pilot Program; Provides Post-Spinoff Status
22/01/2018
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN CINCINNATI, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Patient Home [...]
Patient Growth Equals Big Data for Knalysis Technologies and Canada House Wellness Group
22/01/2018
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Knalysis Technologies “Knalysis”, a subsidiary of Canada House Wellness Group Inc. (CSE:CHV [...]
BioCryst Pharmaceuticals and Idera Pharmaceuticals Announce Merger to Combine Capabilities to Serve More Patients with Rare Diseases
22/01/2018
Filed by BioCryst Pharmaceuticals, Inc. pursuant to Rule 425 Under the Securities Act of 1933 And Deemed Filed Pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Idera Pharmaceuticals, [...]
Anthera Announces Positive Outcome of Second Interim Futility Analysis in the Phase 3 RESULT Clinical Study of Sollpura: Study On Schedule for Topline Data this Quarter
22/01/2018
HAYWARD, Calif., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH ) today announced a positive outcome of the second, pre-specified interim futility analysis for the RESULT Phase 3 clinical [...]

Pages